vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and NORTHERN TECHNOLOGIES INTERNATIONAL CORP (NTIC). Click either name above to swap in a different company.
NORTHERN TECHNOLOGIES INTERNATIONAL CORP is the larger business by last-quarter revenue ($23.3M vs $18.7M, roughly 1.2× CytomX Therapeutics, Inc.). NORTHERN TECHNOLOGIES INTERNATIONAL CORP runs the higher net margin — 1.0% vs -0.8%, a 1.8% gap on every dollar of revenue. On growth, NORTHERN TECHNOLOGIES INTERNATIONAL CORP posted the faster year-over-year revenue change (9.2% vs -25.7%). NORTHERN TECHNOLOGIES INTERNATIONAL CORP produced more free cash flow last quarter ($-479.7K vs $-15.8M). Over the past eight quarters, NORTHERN TECHNOLOGIES INTERNATIONAL CORP's revenue compounded faster (5.8% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Maxar Technologies Inc., was an American space technology company, specializing in geospatial intelligence, Earth observation, and on-orbit satellite servicing, satellite products, and related services. DigitalGlobe and MDA Holdings Company merged to become Maxar Technologies on October 5, 2017.
CTMX vs NTIC — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $23.3M |
| Net Profit | $-154.0K | $237.8K |
| Gross Margin | — | 36.0% |
| Operating Margin | -6.9% | 4.0% |
| Net Margin | -0.8% | 1.0% |
| Revenue YoY | -25.7% | 9.2% |
| Net Profit YoY | 97.6% | -57.6% |
| EPS (diluted) | — | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $23.3M | ||
| Q3 25 | — | $22.3M | ||
| Q2 25 | $18.7M | $21.5M | ||
| Q1 25 | $50.9M | $19.1M | ||
| Q4 24 | $38.1M | $21.3M | ||
| Q3 24 | $33.4M | $23.3M | ||
| Q2 24 | $25.1M | $20.7M | ||
| Q1 24 | $41.5M | $20.8M |
| Q4 25 | — | $237.8K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | $-154.0K | $121.8K | ||
| Q1 25 | $23.5M | $434.3K | ||
| Q4 24 | $18.9M | $561.1K | ||
| Q3 24 | $5.7M | $1.8M | ||
| Q2 24 | $-6.5M | $976.6K | ||
| Q1 24 | $13.8M | $1.7M |
| Q4 25 | — | 36.0% | ||
| Q3 25 | — | 37.9% | ||
| Q2 25 | — | 38.4% | ||
| Q1 25 | — | 35.6% | ||
| Q4 24 | — | 38.3% | ||
| Q3 24 | — | 43.8% | ||
| Q2 24 | — | 38.2% | ||
| Q1 24 | — | 40.0% |
| Q4 25 | — | 4.0% | ||
| Q3 25 | — | 4.2% | ||
| Q2 25 | -6.9% | 4.0% | ||
| Q1 25 | 44.4% | -1.7% | ||
| Q4 24 | 46.4% | 5.2% | ||
| Q3 24 | 12.3% | 11.8% | ||
| Q2 24 | -33.7% | 7.4% | ||
| Q1 24 | 28.1% | 10.6% |
| Q4 25 | — | 1.0% | ||
| Q3 25 | — | -4.9% | ||
| Q2 25 | -0.8% | 0.6% | ||
| Q1 25 | 46.2% | 2.3% | ||
| Q4 24 | 49.6% | 2.6% | ||
| Q3 24 | 17.2% | 7.9% | ||
| Q2 24 | -26.0% | 4.7% | ||
| Q1 24 | 33.3% | 8.2% |
| Q4 25 | — | $0.03 | ||
| Q3 25 | — | $-0.11 | ||
| Q2 25 | — | $0.01 | ||
| Q1 25 | — | $0.04 | ||
| Q4 24 | — | $0.06 | ||
| Q3 24 | — | $0.19 | ||
| Q2 24 | — | $0.10 | ||
| Q1 24 | — | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $6.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $72.4M |
| Total Assets | $175.1M | $104.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $6.4M | ||
| Q3 25 | — | $7.3M | ||
| Q2 25 | $49.0M | $6.8M | ||
| Q1 25 | $47.6M | $5.1M | ||
| Q4 24 | $38.1M | $5.6M | ||
| Q3 24 | $40.6M | $5.0M | ||
| Q2 24 | $43.2M | $5.8M | ||
| Q1 24 | $36.2M | $4.8M |
| Q4 25 | — | $72.4M | ||
| Q3 25 | — | $72.1M | ||
| Q2 25 | $119.9M | $72.4M | ||
| Q1 25 | $25.0M | $69.7M | ||
| Q4 24 | $-456.0K | $70.2M | ||
| Q3 24 | $-23.5M | $71.2M | ||
| Q2 24 | $-31.2M | $68.9M | ||
| Q1 24 | $-31.7M | $68.4M |
| Q4 25 | — | $104.0M | ||
| Q3 25 | — | $102.7M | ||
| Q2 25 | $175.1M | $99.3M | ||
| Q1 25 | $98.5M | $93.7M | ||
| Q4 24 | $120.5M | $94.0M | ||
| Q3 24 | $139.0M | $94.7M | ||
| Q2 24 | $159.2M | $89.3M | ||
| Q1 24 | $184.7M | $87.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $341.9K |
| Free Cash FlowOCF − Capex | $-15.8M | $-479.7K |
| FCF MarginFCF / Revenue | -84.6% | -2.1% |
| Capex IntensityCapex / Revenue | 0.1% | 3.5% |
| Cash ConversionOCF / Net Profit | — | 1.44× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-1.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $341.9K | ||
| Q3 25 | — | $-1.4M | ||
| Q2 25 | $-15.8M | $609.7K | ||
| Q1 25 | $-21.0M | $803.7K | ||
| Q4 24 | $-19.9M | $2.4M | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.5M | $1.9M | ||
| Q1 24 | $-26.0M | — |
| Q4 25 | — | $-479.7K | ||
| Q3 25 | — | $-1.4M | ||
| Q2 25 | $-15.8M | $-171.2K | ||
| Q1 25 | $-21.2M | $293.1K | ||
| Q4 24 | $-20.0M | $1.2M | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | $869.4K | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | -2.1% | ||
| Q3 25 | — | -6.3% | ||
| Q2 25 | -84.6% | -0.8% | ||
| Q1 25 | -41.6% | 1.5% | ||
| Q4 24 | -52.5% | 5.5% | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | 4.2% | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | 0.1% | 3.6% | ||
| Q1 25 | 0.2% | 2.7% | ||
| Q4 24 | 0.2% | 5.7% | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | 5.2% | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | 1.44× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 5.01× | ||
| Q1 25 | -0.89× | 1.85× | ||
| Q4 24 | -1.05× | 4.27× | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | 1.99× | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
NTIC
| Inside The USA To Unaffiliated Customers | $7.5M | 32% |
| Natur Tec | $6.0M | 26% |
| Acobal | $3.6M | 15% |
| Other | $2.7M | 12% |
| BR | $2.1M | 9% |
| Zerust OY | $1.4M | 6% |
